Double Blind Peanut Sublingual Immunotherapy (PN SLIT)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The specific aim of this study is to desensitize peanut-allergic subjects with peanut allergen-specific, sublingual immunotherapy (SLIT) by placing drops of peanut protein under the tongue which will be absorbed. The hypothesis is that peanut SLIT will desensitize patients with peanut allergic reactions by changing the subject's immune system to adapt to peanuts.
Condition | Intervention |
---|---|
Food Hypersensitivity |
Drug: Sublingual Peanut protein Drug: Glycerol saline drops Other: SL |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
Official Title: | A Double-blinded, Placebo-controlled Study of Peanut Sublingual Immunotherapy in Children |
- Subject will successfully pass a double blind placebo controlled food challenge at the end of the study after having been off the sublingual immunotherapy for 2 to 4 weeks. [ Time Frame: End of the study ] [ Designated as safety issue: Yes ]
- The peanut specific IgE will have decreased from the level at the start of the study. [ Time Frame: End of the study ] [ Designated as safety issue: No ]
Estimated Enrollment: | 80 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | December 2016 |
Estimated Primary Completion Date: | December 2016 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active Comparator: SLB01
Subjects who receive the protein at the beginning of the study.
|
Drug: Sublingual Peanut protein
Peanut protein drops which will be placed under the tongue
|
Placebo Comparator: SLB02
Subjects who receive placebo at the beginning of the study.
|
Drug: Glycerol saline drops
Glycerol saline drops which will be placed under the tongue
|
SL
Subjects with peanut allergy receiving no SLIT or Placebo
|
Other: SL
Comparison with SLIT and placebo
|
Detailed Description:
In spite of increased recognition and understanding of food allergies, food-induced anaphylaxis is the single most common cause of anaphylaxis seen in hospital emergency departments, accounting for about one third of anaphylaxis cases seen. It is estimated that about 30,000 food-induced anaphylactic events are seen in U.S. emergency departments each year and that about 200 fatal cases occur in the U.S. each year. Either peanuts or tree nuts cause more than 80% of these reactions.
The goal of this study is to develop peanut sublingual immunotherapy (IT) for patients with peanut allergic reactions. This study is designed to utilize the extensive knowledge of the allergens involved in peanut hypersensitivity to devise an immunotherapeutic approach that would lower the risk of anaphylactic reactions (systemic IgE-mediated allergic reaction) and would down regulate peanut-specific T cells in peanut-allergic patients.
Ages Eligible for Study: | 1 Year to 11 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Peanut IgE > 7kU/L (> 2kU/L for children aged 2 years and under) AND
- History of significant clinical symptoms within 60 minutes after the ingestion of peanuts.
Exclusion Criteria:
- History of severe life-threatening anaphylaxis to peanut,
- Medical history that would prevent a DBPCFC to peanut,
- Unable to cooperate with challenge procedures, or
- Unable to be reached by telephone for follow-up.
United States, North Carolina | |
University of North Carolina | |
Chapel Hill, North Carolina, United States, 27599 |
Principal Investigator: | Wesley Burks, MD | University of North Carolina |
No publications provided
Responsible Party: | Wesley Burks, MD, Chairman, Department of Pediatrics, University of North Carolina, Chapel Hill |
ClinicalTrials.gov Identifier: | NCT00597727 History of Changes |
Other Study ID Numbers: | 00001553 |
Study First Received: | January 7, 2008 |
Last Updated: | September 14, 2012 |
Health Authority: | United States: Institutional Review Board United States: Food and Drug Administration |
Keywords provided by University of North Carolina, Chapel Hill:
Peanut Allergy |
Additional relevant MeSH terms:
Food Hypersensitivity Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Glycerol |
Cryoprotective Agents Protective Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on October 17, 2012